DCGI streamlines drug export approvals, enhances regulatory oversight

Q: How long will it take to read this news story?

The story "DCGI streamlines drug export approvals, enhances regulatory oversight" has 835 words across 31 sentences, which will take approximately 4 - 7 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "DCGI streamlines drug export approvals, enhances regulatory oversight" was covered 5 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 222 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #26474659</li><li>URL: https://beamstart.com/news/dcgi-streamlines-drug-export-approvals-17406575032</li></ul>

Business Standard Logo Business Standard 5h ago

DCGI streamlines drug export approvals, enhances regulatory oversight - Business Standard

Quick Summary:

The move against Aveo Pharma followed a recent BBC investigation that exposed a racket in which a Mumbai-based producer, Aveo Pharmaceuticals, was exporting the unlicensed addictive combination to West African countries such as Nigeria, Ghana, and Côte d'Ivoire.

Raghuvanshi clarified the CDSCO’s stance on SEC deliberations, stating that re-deliberations will only be allowed if new information is presented by a company."We will not allow companies to repeatedly push the same content to SECs," he asserted.

The DCGI’s announcements signal a concerted effort to modernise and strengthen India’s drug regulatory framework, ensuring both domestic safety and responsible export practices.